120 related articles for article (PubMed ID: 12872391)
1. [Therapeutic efficacy of combined application of lamivudine and bushen recipe in treating chronic hepatitis B and its influence on YMDD motif].
Zhou F; Wang LT; Chen JJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Jun; 23(6):417-20. PubMed ID: 12872391
[TBL] [Abstract][Full Text] [Related]
2. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
[TBL] [Abstract][Full Text] [Related]
3. [Influence of a triplex superimposed treatment on HBV replication and mutation during treating chronic hepatitis B].
Wu L; Liu H; Xue P; Lu ZG; Du KF
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):236-8. PubMed ID: 11986694
[TBL] [Abstract][Full Text] [Related]
4. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
Ağca H; Sayıner AA; Sengönül A; Simşek I; Akarsu M
Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
[TBL] [Abstract][Full Text] [Related]
5. [Effect of a Chinese herbal compound and lamivudine combination therapy on patients with chronic hepatitis B and its influence on YMDD motif mutation].
Tu YY; Qiu HX
Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):933, 936. PubMed ID: 16381644
[No Abstract] [Full Text] [Related]
6. [Paying attention to TCM and integrative medicine in treating YMDD mutation of chronic hepatitis B].
Li J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Jan; 28(1):9-10. PubMed ID: 18418959
[No Abstract] [Full Text] [Related]
7. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
Deng H; Lv Y; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
[TBL] [Abstract][Full Text] [Related]
9. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study.
Tan YW; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
Braz J Infect Dis; 2012; 16(3):250-5. PubMed ID: 22729192
[TBL] [Abstract][Full Text] [Related]
10. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
11. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
13. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.
Tan Y; Ding K; Su J; Trinh X; Peng Z; Gong Y; Chen L; Cui Q; Lei N; Chen X; Yu R
PLoS One; 2012; 7(3):e32789. PubMed ID: 22479339
[TBL] [Abstract][Full Text] [Related]
14. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
[TBL] [Abstract][Full Text] [Related]
15. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of Chai Shao Liu Jun Tang for the treatment of chronic hepatitis B].
Chi XL; Wu LM; Jiang JM; Chen PQ; Tian GJ; Xiao HM; Cai GS; Chen Y; Qian Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):440-2. PubMed ID: 19567023
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations.
Calica Utku A; Karabay O
World J Gastroenterol; 2016 Jan; 22(4):1727-8. PubMed ID: 26819537
[TBL] [Abstract][Full Text] [Related]
18. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
Ramezani A; Velayati AA; Roshan MR; Gachkar L; Banifazl M; Keyvani H; Aghakhani A
Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
[TBL] [Abstract][Full Text] [Related]
19. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
[TBL] [Abstract][Full Text] [Related]
20. [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy].
Wang L; Yan J; Zhang ZH; Wang JB; Du YZ; Li XY; Wang YZ
Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):585-8. PubMed ID: 15504286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
